Dr Courtney Davis
Scopus Author ID: 56953596300
Research Group
Department
Research interests
Courtney is a medical and political sociologist with broad research interests in the intersections of science and technology policy, business regulation and public health. For over ten years she has undertaken empirically-based, policy relevant international comparative research investigating the socio-political, economic, cultural and scientific factors underlying trends in regulation and the implications of current techno-scientific standards for public, patient and worker health in relation to two distinct fields of inquiry: pharmaceuticals and occupational health and safety.
Putting patients first in medicines regulation?
Naci, H., Forrest, R. & Davis, C., 30 Nov 2021, In: The BMJ. 375, n2883.Research output: Contribution to journal › Editorial › peer-review
Achieving greater independence from commercial influence in research
Lexchin, J., Bero, L. A., Davis, C. & Gagnon, M. A., 9 Mar 2021, In: The BMJ. 372, n370.Research output: Contribution to journal › Review article › peer-review
Data Transparency and Pharmaceutical Regulation in Europe: Road to Damascus, or Room without a View?
Davis, C., Mulinari, S. & Jefferson, T., 2021, Transparency, Power, and Influence in the Pharmaceutical Industry: Policy Gain or Confidence Game?. Fierlbeck, K., Graham, J. & Herder, M. (eds.). University of Toronto Press, p. 63-94Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review
Failure of Responsive Regulation? Pharmaceutical Marketing, Corporate Impression Management and Off-Label Promotion of Enzalutamide in Europe
Mulinari, S., Davis, C. & Ozieranski, P., 2021, In: Journal of White Collar and Corporate Crime. 2, 2, p. 69-80 12 p.Research output: Contribution to journal › Article › peer-review
Top downloads
- 252
Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012
Research output: Contribution to journal › Article › peer-review
downloads - 251
“Adaptive pathways” to drug authorisation: adapting to industry?
Research output: Contribution to journal › Comment/debate › peer-review
downloads - 199
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Research output: Contribution to journal › Article › peer-review
downloads - 79
Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: Regulatory review methodologies and the importance of 'deep' product reviews
Research output: Contribution to journal › Article › peer-review
downloads - 57
International and Temporal Comparative Analysis of UK and US Drug Safety Regulation in Changing Political Contexts
Research output: Contribution to journal › Article › peer-review
downloads
King's College London - Homepage
© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454